Bendamustine-induced immune hemolytic anemia in a chronic lymphocytic leukemia patient: A case report and review of the literature.
Bendamustine is an alkylating agent approved for the treatment of chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma. There are scant reports on bendamustine-induced immune hemolytic anemia occurring mainly in CLL patients. We report a case of immune hemolytic anemia that developed after exposure to bendamustine in a 70-year-old female with CLL who was previously exposed to fludarabine. Previous exposure to fludarabine is a common finding in the majority of reported cases of bendamustine drug-induced immune hemolytic anemia (DIIHA), including our case. Bendamustine should be suspected as the cause of any hemolytic anemia that develops while on this drug, especially in CLL patients treated previously with fludarabine.
Staten Island University Hospital, 475 Seaview Ave, Staten Island, NY 10305, United States. Electronic address: husamhaddad@yahoo.com.
Housam
H
Haddad
Staten Island University Hospital, 475 Seaview Ave, Staten Island, NY 10305, United States. Electronic address: drfarhan4u@gmail.com.
Farhan
F
Mohammad
Staten Island University Hospital, 475 Seaview Ave, Staten Island, NY 10305, United States. Electronic address: Qun_Dai@siuh.edu.
Qun
Q
Dai
D000368:Aged; D000743:Anemia, Hemolytic / Q000139:chemically induced* / Q000276:immunology; D000069461:Bendamustine Hydrochloride; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects* / Q000276:immunology
D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride
Bendamustine; CLL; Hemolytic anemia